Myelodysplastic syndromes and the role of iron overload

American Journal of Health-System Pharmacy

Volumn 67, Issue SUPPL. 2, 2010, Pages

  Harvey, R Donald ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Blood; Epidemiology; Heavy metal antagonists; Iron overload; Mortality; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEFERASIROX; DEFEROXAMINE; IMMUNOMODULATING AGENT; IRON; IRON CHELATING AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPCIDIN; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANEMIA; CARDIOMYOPATHY; CONFERENCE PAPER; CYTOPENIA; DIABETES MELLITUS; DISEASE COURSE; ENDOCRINE DISEASE; EPIDEMIOLOGICAL DATA; ERYTHROCYTE TRANSFUSION; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LIVER DISEASE; LIVER DYSFUNCTION; LONG TERM CARE; MORBIDITY; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BETA THALASSEMIA; BLAST CELL; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME DELETION; DISEASE CLASSIFICATION; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HORMONE BLOOD LEVEL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON BLOOD LEVEL; IRON INTAKE; LIVER CELL; MACROPHAGE; NEUTROPHIL COUNT; PATIENT COMPLIANCE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RETICULOENDOTHELIAL SYSTEM; SINUSOIDAL OBSTRUCTION SYNDROME; THROMBOCYTE COUNT; Y CHROMOSOME;

EID: 77950613637     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090645     Document Type: Conference Paper

References (35)

1. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005; 56:1-16.
2. List AF, Vardiman J, Issa JP et al. Myelodysplastic Syndromes. In: Hematology 2004. Washington, DC: American Society of Hematology; 2004:297-317.
3. Ma X, Does M, Raza A et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007; 109:1536-1542
4. Miller KB. Myelodysplastic syndromes. Curr Treat Options Oncol. 2000; 1:63-9.
5. Bennett JM. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol. 2005; 32:S3-10.
6. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica. 1998; 83:358-368
7. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89:2079-2088
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes. V.2.2010. www.nccn.org/professional/ physician-gls/PDF/mds.pdf (accessed 2010 Jan 20).
9. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003; 120:187-200. (Pubitemid 36194166)
10. Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology. 2007; 21:43-54.
11. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program). 2005:161-166
12. Thomas ML. Strategies for achieving transfusion independence in myelodysplastic syndromes. Eur J Oncol Nurs. 2007; 11:151-158
13. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999; 341:1986-1995
14. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117:285-297
15. Porter JB. Pathophysiology of iron overload. Hematol Oncol Clin North Am. 2005; 19:7-12.
16. Jabbour E, Kantarjian HM, Koller C et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008; 112:1089-1095
17. Cazzola M, la Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2008:166-175
18. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007; 31(suppl 3):S2-6.
19. Angelucci E, Brittenham GM, McLaren CE et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000; 343:327-331 (Pubitemid 30616698)
20. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin. 2009; 25:139-147
21. Takatoku M, Uchiyama T, Okamoto S et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78:487-494 (Pubitemid 46753591)
22. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23:7594-7603 (Pubitemid 46291823)
23. Maradei SC, Maiolino A, de Azevedo AM et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood. 2009; 114:1270-1275
24. Platzbecker U, Bornhauser M, Germing U et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant. 2008; 14:1217-1225
25. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep. 2003; 2:122-129
26. Terpos E, Mougiou A, Kouraklis A et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002; 118:174-180
27. Rose EH, Abels RI, Nelson RA et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol. 1995; 89:831-837
28. Stasi R, Abruzzese E, Lanzetta G et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005; 16:1921-1927
29. List A, Dewald G, Bennett J et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355:1456-1465 (Pubitemid 44511560)
30. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106:1794-1803
31. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20:2429-2440 (Pubitemid 34525728)
32. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol. 2008; 83:858-861
33. Alessandrino EP, Amadori S, Barosi G et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica. 2002; 87:1286-1306
34. Gattermann N, Porter JB, Lopes LF et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am. 2008; 19:18-25.
35. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol. 2008; 88:24-29